March 7, 2024 @ 11am EST

In this webinar, you will learn:

  • Non-Invasive Liquid Biopsies: Cell-free DNA as a key analyte for non-invasive liquid biopsies for cancer diagnosis and monitoring.
  • Enhanced Cell-Free DNA Recovery: Strategies to improve cell-free DNA recovery, including the use of DNA priming agents like DNA-binding monoclonal antibodies.
  • Fc-Domain Engineering: The process of engineering the Fc-domain of antibodies to modify FcγR interactions, enhancing the effectiveness as DNA priming agents.
  • Antibody Sequencing and Engineering: How de novo antibody sequencing informs the engineering of monoclonal antibodies, optimizing their performance for specific applications.

Circulating tumor DNA (ctDNA), released into the bloodstream by tumor cells, is a promising biomarker for cancer detection, offering noninvasive diagnosis and disease monitoring through standard blood tests. However, the utility of cell-free DNA (cfDNA) is constrained by its scarcity, caused by degradation by circulating nucleases and organ-mediated clearance.

To enhance the sensitivity of ctDNA detection in liquid biopsies, attenuating cfDNA clearance becomes crucial. This can be achieved by employing DNA-binding agents. Monoclonal antibodies (mAbs) that bind directly to cfDNA serve as a DNA priming agent, offering protection from circulating DNAases and extending its half-life in circulation. The application of mAbs as DNA-priming agents significantly boosts ctDNA recovery from the blood by more than 10-fold. This effectively overcomes the limitation of low ctDNA quantities that often restrict the sensitivity of liquid biopsies for oncological purposes.

Antibody Sequencing Enables Fc-Engineering of DNA-Binding Antibodies

De novo antibody sequencing enables the engineering of the Fc-domain of the mAb priming agent, eliminating Fc gamma receptor (FcγR)-mediated clearance, and enhances ctDNA recovery. A comprehensive understanding of the amino acid sequence facilitates informed engineering, allowing for the modification of amino acid sequences to introduce desired antibody functions.

Speaker Bios

Talk to Our Scientists.

We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.

Talk to Our Scientists.

We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics

Talk to our scientists. We have sequenced over 9000+ antibodies and we are eager to help you.